Aspire Biopharma Holdings, Inc. Warrant

Company Overview

Business Model: Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical and supplements company focused on developing and marketing disruptive sublingual delivery technologies for known drugs and nutraceuticals. The Company expects to generate revenue through product sales and potentially through license or collaboration agreements that may include development funding, upfront and milestone payments, and/or royalties.

Market Position: The Company is developing novel sublingual absorption technology for drugs like aspirin, which it believes offers competitive advantages due to faster bioavailability and avoidance of gastrointestinal toxicity compared to traditional oral forms. To its knowledge, there are currently no sublingual aspirin products on the market. Aspire Biopharma Holdings, Inc. also develops nutraceuticals, such as caffeine, melatonin, and vitamin products, utilizing its sublingual technology.

Recent Strategic Developments:

• Reverse Recapitalization: On February 17, 2025, PowerUp Acquisition Corp. completed a reverse recapitalization with Aspire Biopharma, Inc., resulting in Aspire Biopharma Holdings, Inc. becoming the parent company.
• Aspirin Product Development: A successful clinical trial for high-dose sublingual aspirin was completed in July 2025, demonstrating faster aspirin bioavailability and quicker anti-coagulant properties compared to standard oral aspirin. A pre-Investigational New Drug (IND) request was submitted to the FDA on October 31, 2025, with a positive response received on November 13, 2025, approving the proposed next clinical trial. The Company plans to submit a section 505(b)(2) New Drug Application (NDA) to the FDA in late 2026 for treatment of suspected acute myocardial infarction.
• Nutraceutical Product Launches: Aspire Biopharma Holdings, Inc. unveiled and began selling initial versions of its sublingual caffeine products under the "Buzz Bomb" trademark in the third quarter of 2025, following trial runs and consumer testing in Q2 2025. A manufacturing contract with Supranaturals for 2,000,000 units of the caffeine supplement commenced marketing on January 15, 2026.
• Intellectual Property Expansion: The Company filed a new patent application in October 2024 for a high-dose sublingually administered aspirin product using a micelle variation. An "Omnibus Patent" was filed in October 2025 to extend intellectual property rights to other drugs and supplements, including melatonin, nicotine, alprazolam, meclizine, clopidogrel, ondansetron, and vitamins D, E, and K.
• Financing Activities: In February 2025, the Company issued $3,750,000 in 20% original issue discount senior secured convertible debentures. In August 2025, it issued convertible notes with an aggregate principal amount of $9,687,500 for a subscription price of $7,750,000. A Second Equity Line of Credit (ELOC) Agreement was entered into in November 2025, providing the right to direct Arena Business Solutions Global SPC II, Ltd. to purchase up to $100,000,000 in common stock over 24 months. In January 2026, approximately $1.75 million in debt was exchanged for common stock. In February 2026, the Company closed on an aggregate of 13,750 shares of Series A Convertible Preferred Stock, generating gross proceeds of $11,000,000, including the conversion of $943,801 in existing debt.
• Nasdaq Compliance: The Company regained compliance with Nasdaq's Bid Price Rule on February 3, 2026, and the Market Value of Listed Securities (MVLS) Rule on February 18, 2026, after facing delisting notices in April and October 2025.

Geographic Footprint: The Company's primary operational regions and markets are the United States, where its clinical trials and initial commercialization efforts are focused. Revenue in 2025 was primarily from the United States ($6,153), with minor contributions from Canada ($30) and the United Kingdom ($19).

Financial Performance

Revenue Analysis

Profitability Metrics (Year Ended December 31, 2025):

• Gross Margin: -1.87%
• Operating Margin: -3119.9%
• Net Margin: -3947.3%

Investment in Growth (Year Ended December 31, 2025):

• R&D Expenditure: $0.923914 million (14900.26% of revenue)
• Capital Expenditures: Not explicitly disclosed.
• Strategic Investments: Not explicitly disclosed as separate line items.

Business Segment Analysis

Aspire Biopharma Holdings, Inc. operates as a single reportable segment, as determined by its Chief Executive Officer, who serves as the chief operating decision-maker. Therefore, a detailed breakdown by business segment is not applicable.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Aspire Biopharma Holdings, Inc. has never declared or paid any cash dividends on its common stock and intends to retain any future earnings.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $1.003904 million
• Total Debt: $5.175254 million (Comprising notes payable – related party, loan and transfer notes payable – related party, subscription agreement loans, convertible note, and promissory note fee – related party)
• Net Cash Position: $(4.171350) million (Net Debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile:
  • February 2025 Convertible Debentures: $1.146236 million outstanding as of December 31, 2025, with a remaining term of 0.13 years.
  • August 2025 Notes: $0.144241 million outstanding as of December 31, 2025, with a remaining term of 0.14 years.
  • Notes payable – related party: $0.885564 million outstanding as of December 31, 2025.
  • Loan and transfer notes payable – related party: $0.499214 million outstanding as of December 31, 2025.
  • Subscription agreement loans: $1.500000 million outstanding as of December 31, 2025.
  • Promissory note fee – related party: $1.000000 million outstanding as of December 31, 2025.
  • January 2026 Debentures: $2,173,913 aggregate principal amount issued January 26, 2026, with a maturity date of April 23, 2026 (paid in full February 6, 2026).

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: $(4.923488) million
• Free Cash Flow: Not explicitly disclosed.
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Aspire Biopharma Holdings, Inc. currently contracts with third parties for the manufacture of its product candidates for preclinical studies, clinical trials, and commercial sale. The Company does not own or operate its own manufacturing facilities and has no current plans to build them. It relies on personnel with manufacturing experience to oversee relationships with contract manufacturers.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturer (Aspirin): Glatt - Produced high-dose sublingual aspirin for clinical trials in Q4 2024 and March 2025. Has capabilities for potential commercial use, but current capacity may be insufficient for planned needs.
• Fill-and-Finish Contract Manufacturer: Converts aspirin product manufactured by Glatt into packaged drug product for clinical trials.
• Contract Development and Manufacturing Organization (CDMO) (Aspirin): Microsize (Quakertown, PA) - Engaged in January 2026 to manufacture aspirin products for the next round of clinical trials for high-dose aspirin for myocardial infarction.
• Nutrition and Supplement Manufacturer (Caffeine): Desert Stream, Inc. (Nephi, UT) - Manufactured trial runs of sublingual caffeine supplement in Q2 2025 through its wholly-owned subsidiary Buzz Bomb Caffeine Company LC.
• Nutrition and Supplement Manufacturer (Caffeine): Supranaturals (Springville, UT) - Entered into a manufacturing contract to produce 2,000,000 units of the "Buzz Bomb" caffeine supplement, with marketing commencing January 15, 2026.

Facility Network:

• Manufacturing: Relies entirely on third-party contract manufacturers (e.g., Glatt's New Jersey facility, Microsize in Quakertown, PA, Desert Stream, Inc. in Nephi, UT, Supranaturals in Springville, UT).
• Research & Development: Not explicitly detailed, but scientists are involved in formulation development.
• Distribution: Not yet established for aspirin products; plans to build a focused sales and marketing organization in the United States or license products.

Operational Metrics: Not explicitly disclosed in a quantifiable manner beyond clinical trial results.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Plans to build a focused sales and marketing organization in the United States for its prescription aspirin products, targeting the heart attack and stroke prevention market through hospitals and/or specialty care sales forces.
• Licensing: Actively considering licensing its aspirin products and has received inquiries.
• Digital Platforms: Sells nutraceutical products directly to customers from its website (e.g., buzzbombcaffeine.com).

Customer Portfolio: Enterprise Customers: Not explicitly detailed. Strategic Partnerships: Not explicitly detailed. Customer Concentration: Not explicitly detailed.

Geographic Revenue Distribution (Year Ended December 31, 2025):

• United States: 99.2% of total revenue ($6,153)
• Canada: 0.5% of total revenue ($30)
• United Kingdom: 0.3% of total revenue ($19)
• Growth Markets: Not explicitly detailed beyond the above.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is characterized by intense competition and rapid innovation. The Company's sublingual absorption technology is considered novel, with no currently approved sublingual aspirin products on the market.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Bayer aspirin: Traditional oral aspirin products.
• Advil: Over-the-counter pain relief.
• Tylenol: Over-the-counter pain relief.
• Other major pharmaceutical, specialty pharmaceutical, and biotechnology companies: Companies with substantially greater financial, technical, and human resources, and greater experience in product development, regulatory approvals, and commercialization.
• Academic institutions and government agencies: Sources of potential competing technologies.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in the biopharmaceutical and nutraceutical industries.

Competitive Response Strategy: Aspire Biopharma Holdings, Inc. aims to leverage its sublingual absorption technology to differentiate its products based on efficacy, safety, convenience of administration, and rapid treatment impact. It plans to submit a 505(b)(2) NDA for its high-dose sublingual aspirin, capitalizing on aspirin's established history and clinical trial results.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Limited Operating History: Early-stage company with no assurance of profitability.
• Product Market Acceptance: Even if approved, sublingual aspirin may not gain broad acceptance among physicians, patients, and the medical community, especially given the novelty of the delivery mechanism for aspirin.
• Competition: Intense competition from companies with greater resources and experience, potentially developing safer, more effective, or less expensive products.
• International Trade Disputes: Potential adverse impact from tariffs or trade restrictions on costs and supply chains.
• Geopolitical Exposure: Financial position and operations could be materially and adversely affected by global conflicts (e.g., Ukraine, Israel-Hamas) due to increased market volatility and financing availability.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Manufacturing Reliance: Dependence on a limited number of contract manufacturers (e.g., Glatt, Microsize, Supranaturals) for clinical and commercial supplies, exposing the Company to risks of delays, shortages, quality issues, and increased costs if manufacturers fail to comply with regulations or meet demand.
• Hazardous Materials: Reliance on third-party manufacturers using hazardous and biological materials, with potential liability for damages if mishandled.
• No Internal Sales/Marketing: Lack of established sales, marketing, or distribution infrastructure, requiring significant capital and time to build or reliance on third-party collaborators.
• Clinical Development Uncertainty: Lengthy, expensive, and uncertain clinical trial process; results of earlier trials may not be predictive of future outcomes. Delays in patient enrollment or trial completion could harm commercial prospects.
• Undesirable Side Effects: Product candidates may cause side effects, leading to clinical trial halts, regulatory approval delays/denials, or limited commercial potential.
• Cybersecurity Threats: Exposure to advanced and persistent cyberattacks, security breaches, and system disruptions that could compromise confidential information or operations.

Financial & Regulatory Risks

Market & Financial Risks:

• Substantial Additional Financing Required: Significant capital needs for clinical development and commercialization; failure to obtain financing could force delays or termination of efforts.
• Net Losses: Incurred substantial net losses since inception and anticipates continued losses.
• Dilution: Future equity issuances for financing could dilute existing stockholders' ownership.
• Product Liability: Inherent risk of product liability claims from clinical testing and commercialization, potentially leading to substantial liabilities or limitations on commercialization.
• Nasdaq Listing Compliance: Previously faced delisting notices for minimum Market Value of Listed Securities and Bid Price Rule, though compliance was regained in February 2026. Regulatory & Compliance Risks:
• Extensive Regulation: Highly regulated biopharmaceutical industry, requiring substantial time and financial resources for research, development, testing, manufacturing, and marketing approvals (e.g., FDA).
• Unproven Regulatory Pathway: Novel sublingual technology for aspirin has an unproven regulatory approval pathway.
• Non-Compliance Penalties: Failure to comply with regulatory requirements (e.g., FDCA, GLP, cGMP) could result in delays, sanctions, or refusal of approvals.
• Employee Misconduct: Risk of fraudulent or illegal activity by employees, contractors, or partners, including noncompliance with regulatory standards and healthcare fraud and abuse laws.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Sublingual Delivery Mechanisms: Development of patent-pending formulations for rapid sublingual absorption of drugs and nutraceuticals, bypassing the gastrointestinal tract, allowing for rapid treatment impact and high-dose absorption.
• Micelle Variation Technology: A second patent application filed in October 2024 for a high-dose sublingually administered aspirin product using a micelle variation, applicable to a variety of substances. Innovation Pipeline:
• Aspirin: High-dose sublingual aspirin for myocardial infarction (NDA submission planned for late 2026). Ongoing research for antithrombotic and analgesic effects in other therapeutic indications.
• Melatonin: Working formulation for 3mg, 5mg, and 10mg sublingual sleep-aid products.
• Vitamins: Working formulations for sublingually administered vitamins D, E, and K.
• ED Medication: Working formulation for a sublingual erectile dysfunction product (FDA approval likely 2-3 years).
• Caffeine Products: Single-serving sublingual pre-workout supplement and "coffee or soda replacement" with health benefits.
• Other Formulations: Anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide. Considering anti-psychotic products and seizure medication.

Intellectual Property Portfolio:

• Patent Strategy: Seeks U.S. and international patent protection for proprietary drug candidates, inventions, and improvements. Relies on trade secrets and know-how.
• Patent Holdings:
  • International Application No. PCT/US2024/022318 (claims priority to U.S. Application No. 63/456,290): Nominal expiration March 29, 2044. Covers composition of matter (formulations), product-by-process, and uses.
  • U.S. Application No. 63/702,381 (priority for PCT application intended October 1, 2025): Nominal expiration October 1, 2045. Covers high-dose sublingual aspirin using micelle variation.
  • Omnibus Patent (application 63/890,248 filed September 29, 2025): Covers melatonin, caffeine, nicotine, and vitamins (A, D, E, K).
  • Other Pending Patents: Alprazolam (63/957,370, filed January 9, 2026), Clopidogrel (63/957,361, filed January 9, 2026), Meclizine (63/971,320, filed January 29, 2026), Ondansetron (63/970,377, filed January 28, 2026).
• Trademark Holdings:
  • "Buzz Bomb" (Registration No. 99146781, Approved April 20, 2025; Pending applications 99447682, 99287743).
  • "Caffeine…Accelerated" (Registration No. 99287826, Approved July 16, 2025).
  • Pending trademarks: "Bomb Squad" (97755121), "Coffee Shot" (99169570, 99287764), "Without The Cup" (99287858), "Instaprin" (98793226).
• Domain Names: aspire-biopharma.com, aspirebiolabs.com, buzzbombcaffeine.com.
• IP Litigation: Not explicitly disclosed as material.

Technology Partnerships: Not explicitly detailed beyond manufacturing agreements.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company is currently undergoing a search for a permanent CEO.

Board Composition: The Board consists of four members: Kraig T. Higginson (Class III, Chairman), Philip Balatsos (Class II, Director), Edward J. Kimball (Class II, Director), and Howard Doss (Class III, Director). The Board is classified into three classes with staggered terms. Edward J. Kimball, Philip Balatsos, and Howard Doss are determined to be independent directors under Nasdaq listing standards. The Audit Committee is comprised of Howard Doss (Chairman), Edward Kimball, and Philip Balatsos, with Howard Doss qualifying as an "audit committee financial expert." The Compensation Committee is comprised of Edward Kimball, Howard Doss, and Philip Balatsos, with Philip Balatsos serving as chairman.

Human Capital Strategy

Workforce Composition:

• Total Employees: Not explicitly disclosed.
• Geographic Distribution: Not explicitly disclosed.
• Skill Mix: Not explicitly disclosed.

Talent Management: Acquisition & Retention:

• Hiring Strategy: The 2024 Stock Incentive Plan aims to attract, retain, and motivate employees, directors, and consultants by providing equity ownership opportunities.
• Retention Metrics: Not explicitly disclosed.
• Employee Value Proposition: Equity incentive plans (RSUs, stock options), annual base salary, performance-based bonuses, employee benefit plans, and reimbursement of business expenses for executive officers.

Diversity & Development: Not explicitly disclosed.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Federal Food, Drug and Cosmetic Act (FDCA): Candidate products are regulated under FDCA and applicable implementing regulations and guidance in the United States.
• Good Laboratory Practice (GLP) and Current Good Manufacturing Practice (cGMP): Preclinical tests and manufacturing must comply with GLP and cGMP requirements.
• Investigational New Drug (IND) Application: Required before testing compounds in humans, though some human bioavailability trials of FDA-approved active ingredients may be exempt.
• New Drug Application (NDA): Required for marketing approval of drug products. Aspire Biopharma Holdings, Inc. plans a 505(b)(2) NDA submission for its high-dose sublingual aspirin.
• Over-the-Counter (OTC) Monograph: The Company may consider selling aspirin products consistent with the OTC Monograph for expedited market access, potentially as an oral administration initially, while discussing sublingual administration with the FDA as an exception.
• International Compliance: Subject to regulations in other countries and jurisdictions (e.g., European Union) for research, development, manufacturing, pricing, and marketing.

Trade & Export Controls: Not explicitly detailed beyond general statements about import/export regulation.

Legal Proceedings: No material litigation, arbitration, or governmental proceeding currently pending against the Company or its management team.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate (2025): 0% (Pretax book loss of $(24,480,848), statutory federal income tax of $(5,140,978), offset by change in valuation allowance of $2,828,659 and non-deductible transaction costs of $3,171,730, and change in derivative liability of $(810,787)).
• Effective Tax Rate (2024): 0.08% (Pretax book loss of $(1,308,859), with a minimum tax liability of $1,013).
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The One Big Beautiful Bill Act (Public Law 119-21) enacted in July 2025 did not have a material impact on the Company's consolidated financial statements for 2025.